Patient Group and Industry Recognition and Awards


2016 Marcum Award

CSL Behring received the 2016 Marcum Innovator Breakthrough Award for pioneering new advancements in the biotech/healthcare field.

2016 World Recognition Distinguished General Counsel

The Directors Roundtable honored CSL General Counsel Greg Boss with the 2016 World Recognition of Distinguished General Counsel.

2016 Healthcare CEO Enterprise Award

CSL CEO and Managing Director Paul Perreault received Philadelphia Alliance for Capital and Technologies’ Healthcare CEO Enterprise Award.


2015 Corporate Leadership Award

The National Hemophilia Foundation recognized CSL Behring for its longstanding commitment to delivering innovative products and programs that advance the care of the bleeding disorders community.

2015 Swiss Employer Award

CSL Behring was selected for the award from among 118 companies in Switzerland and Lichtenstein by Bilanz magazine in the Companies with 1000+ Employees category.


2012 Enterprise Awards: Life Sciences Company of the Year Finalist

Greater Philadelphia Alliance for Capital and Technologies recognized CSL Behring as one of the region’s "most outstanding life sciences companies."

2012 Patient Impact Award Finalist

Pennsylvania Bio recognized CSL Behring as a Patient Impact Award finalist for "making a profound, positive difference in the lives of patients."

2012 EURORDIS Award

Presented to CSL Behring by EURORDIS (European Organisation for Rare Diseases) for "pioneering work in developing and manufacturing therapies used to treat rare and serious medical conditions."


2011 Life Sciences Company of the Year

The Philadelphia Business Journal and Pennsylvania Bio presented the award to CSL Behring based on our portfolio of life-enhancing and lifesaving therapies for people with rare and serious diseases, and praised CSL Behring as a company that "makes medical miracles in our community."

World’s Most Innovative Companies

CSL Limited was ranked in Forbes magazine’s list of the world’s Top 50 most innovative companies.

NORD 2011 Corporate Award

Presented to CSL Behring by NORD (National Organization for Rare Disorders) for development of Factor XIII concentrate [human], the first product intended to prevent bleeding in people with the rare genetic defect, congenital Factor XIII deficiency.


2010 Sustainable Company of the Year

Ethical Investor selected CSL Limited Company of the Year for "leading its sector on environmental, social and governance (ESG) issues, and strategically supporting sustainability."


2009 Tell Award

The Swiss government presented the award to CSL Behring for exceptional innovations in state-of-the-art manufacturing in its Bern facility and for novel protein therapies.

NORD 2009 Corporate Award

Presented to CSL Behring for developing and marketing the U.S.'s first and only treatment for acute bleeding episodes in patients with congenital fibrinogen deficiency, an extremely rare, potentially life-threatening bleeding disorder.

LinkedIn Twitter Facebook Google+